TGF-β1 stimulates human at1 receptor expression in lung fibroblasts by cross talk between the Smad, p38 MAPK, JNK, and PI3K signaling pathways

Mickey M. Martin, Jessica A. Buckenberger, Jinmai Jiang, Geraldine E. Malana, Daren L. Knoell, David S. Feldman, Terry S. Elton

Research output: Contribution to journalArticle

67 Citations (Scopus)

Abstract

Both angiotensin II (ANG II) and transforming growth factor-β1 (TGF-β1) are thought to be involved in mediating pulmonary fibrosis. Interactions between the reninangiotensin system (RAS) and TGF-β1 have been well documented, with most studies describing the effect of ANG II on TGF-β1 expression. However, recent gene expression profiling experiments demonstrated that the angiotensin II type 1 receptor (AT1R) gene was a novel TGF-β1 target in human adult lung fibroblasts. In this report, we show that TGF-β1 augments human AT1R (hAT1R) steady-state mRNA and protein levels in a dose- and time-dependent manner in primary human fetal pulmonary fibroblasts (hPFBs). Nuclear run-on experiments demonstrate that TGF-β1 transcriptionally activates the hAT1R gene and does not influence hAT1R mRNA stability. Pharmacological inhibitors and specific siRNA knockdown experiments demonstrate that the TGF-β1 type 1 receptor (TβRI/ALK5), Smad2/3, and Smad4 are essential for TGF-β1-stimulated hAT1R expression. Additional pharmacological inhibitor and small interference RNA experiments also demonstrated that p38 MAPK, JNK, and phosphatidylinositol 3-kinase (PI3K) signaling pathways are also involved in the TGF-β1-stimulated increase in hAT1R density. Together, our results suggest an important role for cross talk among Smad, p38 MAPK, JNK, and PI3K pathways in mediating the augmented expression of hAT1R following TGF-β1 treatment in hPFB. This study supports the hypothesis that a self-potentiating loop exists between the RAS and the TGF-β1 signaling pathways and suggests that ANG II and TGF-β1 may cooperate in the pathogenesis of pulmonary fibrosis. The synergy between these systems may require that both pathways be simultaneously inhibited to treat fibrotic lung disease.

Original languageEnglish (US)
Pages (from-to)L790-L799
JournalAmerican Journal of Physiology - Lung Cellular and Molecular Physiology
Volume293
Issue number3
DOIs
StatePublished - Sep 1 2007

Fingerprint

Phosphatidylinositol 3-Kinase
Transforming Growth Factors
p38 Mitogen-Activated Protein Kinases
Fibroblasts
Lung
Angiotensin II
Angiotensin Type 1 Receptor
Pulmonary Fibrosis
Pharmacology
RNA Stability
Gene Expression Profiling
RNA Interference
Small Interfering RNA
Lung Diseases
Genes

Keywords

  • Angiotensin II
  • G protein-coupled receptors
  • Mitogen-activated protein kinase
  • Phosphatidylinositol 3-kinase
  • Pulmonary fibrosis
  • Transforming growth factor-β1
  • c-Jun NH -terminal kinase

ASJC Scopus subject areas

  • Physiology
  • Pulmonary and Respiratory Medicine
  • Physiology (medical)
  • Cell Biology

Cite this

TGF-β1 stimulates human at1 receptor expression in lung fibroblasts by cross talk between the Smad, p38 MAPK, JNK, and PI3K signaling pathways. / Martin, Mickey M.; Buckenberger, Jessica A.; Jiang, Jinmai; Malana, Geraldine E.; Knoell, Daren L.; Feldman, David S.; Elton, Terry S.

In: American Journal of Physiology - Lung Cellular and Molecular Physiology, Vol. 293, No. 3, 01.09.2007, p. L790-L799.

Research output: Contribution to journalArticle

Martin, Mickey M. ; Buckenberger, Jessica A. ; Jiang, Jinmai ; Malana, Geraldine E. ; Knoell, Daren L. ; Feldman, David S. ; Elton, Terry S. / TGF-β1 stimulates human at1 receptor expression in lung fibroblasts by cross talk between the Smad, p38 MAPK, JNK, and PI3K signaling pathways. In: American Journal of Physiology - Lung Cellular and Molecular Physiology. 2007 ; Vol. 293, No. 3. pp. L790-L799.
@article{d57760dab56d471f94342231de2ade4e,
title = "TGF-β1 stimulates human at1 receptor expression in lung fibroblasts by cross talk between the Smad, p38 MAPK, JNK, and PI3K signaling pathways",
abstract = "Both angiotensin II (ANG II) and transforming growth factor-β1 (TGF-β1) are thought to be involved in mediating pulmonary fibrosis. Interactions between the reninangiotensin system (RAS) and TGF-β1 have been well documented, with most studies describing the effect of ANG II on TGF-β1 expression. However, recent gene expression profiling experiments demonstrated that the angiotensin II type 1 receptor (AT1R) gene was a novel TGF-β1 target in human adult lung fibroblasts. In this report, we show that TGF-β1 augments human AT1R (hAT1R) steady-state mRNA and protein levels in a dose- and time-dependent manner in primary human fetal pulmonary fibroblasts (hPFBs). Nuclear run-on experiments demonstrate that TGF-β1 transcriptionally activates the hAT1R gene and does not influence hAT1R mRNA stability. Pharmacological inhibitors and specific siRNA knockdown experiments demonstrate that the TGF-β1 type 1 receptor (TβRI/ALK5), Smad2/3, and Smad4 are essential for TGF-β1-stimulated hAT1R expression. Additional pharmacological inhibitor and small interference RNA experiments also demonstrated that p38 MAPK, JNK, and phosphatidylinositol 3-kinase (PI3K) signaling pathways are also involved in the TGF-β1-stimulated increase in hAT1R density. Together, our results suggest an important role for cross talk among Smad, p38 MAPK, JNK, and PI3K pathways in mediating the augmented expression of hAT1R following TGF-β1 treatment in hPFB. This study supports the hypothesis that a self-potentiating loop exists between the RAS and the TGF-β1 signaling pathways and suggests that ANG II and TGF-β1 may cooperate in the pathogenesis of pulmonary fibrosis. The synergy between these systems may require that both pathways be simultaneously inhibited to treat fibrotic lung disease.",
keywords = "Angiotensin II, G protein-coupled receptors, Mitogen-activated protein kinase, Phosphatidylinositol 3-kinase, Pulmonary fibrosis, Transforming growth factor-β1, c-Jun NH -terminal kinase",
author = "Martin, {Mickey M.} and Buckenberger, {Jessica A.} and Jinmai Jiang and Malana, {Geraldine E.} and Knoell, {Daren L.} and Feldman, {David S.} and Elton, {Terry S.}",
year = "2007",
month = "9",
day = "1",
doi = "10.1152/ajplung.00099.2007",
language = "English (US)",
volume = "293",
pages = "L790--L799",
journal = "American Journal of Physiology - Renal Physiology",
issn = "0363-6127",
publisher = "American Physiological Society",
number = "3",

}

TY - JOUR

T1 - TGF-β1 stimulates human at1 receptor expression in lung fibroblasts by cross talk between the Smad, p38 MAPK, JNK, and PI3K signaling pathways

AU - Martin, Mickey M.

AU - Buckenberger, Jessica A.

AU - Jiang, Jinmai

AU - Malana, Geraldine E.

AU - Knoell, Daren L.

AU - Feldman, David S.

AU - Elton, Terry S.

PY - 2007/9/1

Y1 - 2007/9/1

N2 - Both angiotensin II (ANG II) and transforming growth factor-β1 (TGF-β1) are thought to be involved in mediating pulmonary fibrosis. Interactions between the reninangiotensin system (RAS) and TGF-β1 have been well documented, with most studies describing the effect of ANG II on TGF-β1 expression. However, recent gene expression profiling experiments demonstrated that the angiotensin II type 1 receptor (AT1R) gene was a novel TGF-β1 target in human adult lung fibroblasts. In this report, we show that TGF-β1 augments human AT1R (hAT1R) steady-state mRNA and protein levels in a dose- and time-dependent manner in primary human fetal pulmonary fibroblasts (hPFBs). Nuclear run-on experiments demonstrate that TGF-β1 transcriptionally activates the hAT1R gene and does not influence hAT1R mRNA stability. Pharmacological inhibitors and specific siRNA knockdown experiments demonstrate that the TGF-β1 type 1 receptor (TβRI/ALK5), Smad2/3, and Smad4 are essential for TGF-β1-stimulated hAT1R expression. Additional pharmacological inhibitor and small interference RNA experiments also demonstrated that p38 MAPK, JNK, and phosphatidylinositol 3-kinase (PI3K) signaling pathways are also involved in the TGF-β1-stimulated increase in hAT1R density. Together, our results suggest an important role for cross talk among Smad, p38 MAPK, JNK, and PI3K pathways in mediating the augmented expression of hAT1R following TGF-β1 treatment in hPFB. This study supports the hypothesis that a self-potentiating loop exists between the RAS and the TGF-β1 signaling pathways and suggests that ANG II and TGF-β1 may cooperate in the pathogenesis of pulmonary fibrosis. The synergy between these systems may require that both pathways be simultaneously inhibited to treat fibrotic lung disease.

AB - Both angiotensin II (ANG II) and transforming growth factor-β1 (TGF-β1) are thought to be involved in mediating pulmonary fibrosis. Interactions between the reninangiotensin system (RAS) and TGF-β1 have been well documented, with most studies describing the effect of ANG II on TGF-β1 expression. However, recent gene expression profiling experiments demonstrated that the angiotensin II type 1 receptor (AT1R) gene was a novel TGF-β1 target in human adult lung fibroblasts. In this report, we show that TGF-β1 augments human AT1R (hAT1R) steady-state mRNA and protein levels in a dose- and time-dependent manner in primary human fetal pulmonary fibroblasts (hPFBs). Nuclear run-on experiments demonstrate that TGF-β1 transcriptionally activates the hAT1R gene and does not influence hAT1R mRNA stability. Pharmacological inhibitors and specific siRNA knockdown experiments demonstrate that the TGF-β1 type 1 receptor (TβRI/ALK5), Smad2/3, and Smad4 are essential for TGF-β1-stimulated hAT1R expression. Additional pharmacological inhibitor and small interference RNA experiments also demonstrated that p38 MAPK, JNK, and phosphatidylinositol 3-kinase (PI3K) signaling pathways are also involved in the TGF-β1-stimulated increase in hAT1R density. Together, our results suggest an important role for cross talk among Smad, p38 MAPK, JNK, and PI3K pathways in mediating the augmented expression of hAT1R following TGF-β1 treatment in hPFB. This study supports the hypothesis that a self-potentiating loop exists between the RAS and the TGF-β1 signaling pathways and suggests that ANG II and TGF-β1 may cooperate in the pathogenesis of pulmonary fibrosis. The synergy between these systems may require that both pathways be simultaneously inhibited to treat fibrotic lung disease.

KW - Angiotensin II

KW - G protein-coupled receptors

KW - Mitogen-activated protein kinase

KW - Phosphatidylinositol 3-kinase

KW - Pulmonary fibrosis

KW - Transforming growth factor-β1

KW - c-Jun NH -terminal kinase

UR - http://www.scopus.com/inward/record.url?scp=34548424486&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34548424486&partnerID=8YFLogxK

U2 - 10.1152/ajplung.00099.2007

DO - 10.1152/ajplung.00099.2007

M3 - Article

C2 - 17601799

AN - SCOPUS:34548424486

VL - 293

SP - L790-L799

JO - American Journal of Physiology - Renal Physiology

JF - American Journal of Physiology - Renal Physiology

SN - 0363-6127

IS - 3

ER -